1. Home
  2. QTTB vs MGIH Comparison

QTTB vs MGIH Comparison

Compare QTTB & MGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTTB
  • MGIH
  • Stock Information
  • Founded
  • QTTB 2015
  • MGIH 1978
  • Country
  • QTTB United States
  • MGIH Hong Kong
  • Employees
  • QTTB N/A
  • MGIH N/A
  • Industry
  • QTTB Biotechnology: Pharmaceutical Preparations
  • MGIH Publishing
  • Sector
  • QTTB Health Care
  • MGIH Consumer Discretionary
  • Exchange
  • QTTB Nasdaq
  • MGIH Nasdaq
  • Market Cap
  • QTTB 19.0M
  • MGIH 17.3M
  • IPO Year
  • QTTB N/A
  • MGIH 2023
  • Fundamental
  • Price
  • QTTB $1.55
  • MGIH $1.59
  • Analyst Decision
  • QTTB Hold
  • MGIH
  • Analyst Count
  • QTTB 8
  • MGIH 0
  • Target Price
  • QTTB $24.00
  • MGIH N/A
  • AVG Volume (30 Days)
  • QTTB 97.2K
  • MGIH 12.1K
  • Earning Date
  • QTTB 08-07-2025
  • MGIH 07-07-2025
  • Dividend Yield
  • QTTB N/A
  • MGIH N/A
  • EPS Growth
  • QTTB N/A
  • MGIH N/A
  • EPS
  • QTTB N/A
  • MGIH N/A
  • Revenue
  • QTTB N/A
  • MGIH $28,866,993.00
  • Revenue This Year
  • QTTB N/A
  • MGIH N/A
  • Revenue Next Year
  • QTTB N/A
  • MGIH N/A
  • P/E Ratio
  • QTTB N/A
  • MGIH N/A
  • Revenue Growth
  • QTTB N/A
  • MGIH N/A
  • 52 Week Low
  • QTTB $1.38
  • MGIH $1.32
  • 52 Week High
  • QTTB $53.79
  • MGIH $6.83
  • Technical
  • Relative Strength Index (RSI)
  • QTTB 40.47
  • MGIH 49.50
  • Support Level
  • QTTB $1.47
  • MGIH $1.52
  • Resistance Level
  • QTTB $1.65
  • MGIH $1.71
  • Average True Range (ATR)
  • QTTB 0.12
  • MGIH 0.09
  • MACD
  • QTTB -0.02
  • MGIH -0.00
  • Stochastic Oscillator
  • QTTB 15.69
  • MGIH 36.00

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

About MGIH Millennium Group International Holdings Limited

Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.

Share on Social Networks: